BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37465317)

  • 21. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
    Leng J; Li DR; Huang LM; Ji XH; Wang DL
    Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Retrospective Cohort Study Examining the Effects of Anti-PD-1 Antibody in Combination with Apatinib in Patients Previously Treated for Her2-Negative Advanced Gastric/Gastroesophageal Junction Cancer.
    Hou XF; Zhang XX; Li S; Wu C; Chen XB
    J Clin Pharmacol; 2023 Jul; 63(7):769-775. PubMed ID: 37005358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third-line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study.
    Li C; Yu F; Xu W
    J Clin Pharm Ther; 2022 Dec; 47(12):2325-2334. PubMed ID: 36495117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
    Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
    Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
    Wang T; Tang J; Yang H; Yin R; Zhang J; Zhou Q; Liu Z; Cao L; Li L; Huang Y; Jiang K; Wang W; She F; Guan N; Hou Z; Li N; Wu L
    JAMA Oncol; 2022 Aug; 8(8):1169-1176. PubMed ID: 35771546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma.
    Yang Q; Li G; Wu X; Lin H; Wu W; Xie X; Zhu Y; Cai W; Shi C; Zhuo S
    Front Oncol; 2023; 13():1136366. PubMed ID: 37064142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.
    Sun Y; Fan Y; Ye Z; Dong J; Zhang L; Peng Y
    Ir J Med Sci; 2023 Jun; 192(3):1033-1040. PubMed ID: 35819743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
    Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
    Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancer.
    Xu J; Liu X; Yang S; Shi Y
    J Cancer Res Ther; 2022 Sep; 18(5):1425-1431. PubMed ID: 36204892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of apatinib on multiple advanced-stage nongastric cancers.
    Wu X; Wang H; Wu Y; Jin J; Zhan Y; Zhu G; Zhang F; Zhang C; Gan J; Li W
    J Cancer Res Ther; 2019; 15(4):836-841. PubMed ID: 31436240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Summary of clinical research progression of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer].
    Yang MD; Gao J; Liu XL; Yang WH; Lu HX
    Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):594-597. PubMed ID: 32842450
    [No Abstract]   [Full Text] [Related]  

  • 33. Changing patterns of Serum CEA and CA199 for Evaluating the Response to First-line Chemotherapy in Patients with Advanced Gastric Adenocarcinoma.
    He B; Zhang HQ; Xiong SP; Lu S; Wan YY; Song RF
    Asian Pac J Cancer Prev; 2015; 16(8):3111-6. PubMed ID: 25921105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
    Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
    Pan Z; Luo Z; He H; Chen Y; Zhao B; Yang Z; Li L
    J Ovarian Res; 2023 Feb; 16(1):44. PubMed ID: 36823642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment.
    Liao X; Li H; Liu Z; Liao S; Li Q; Liang C; Huang Y; Xie M; Wei J; Li Y
    Medicine (Baltimore); 2018 Dec; 97(50):e13635. PubMed ID: 30558053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.
    Deng YY; Jiang DY; Zhu PF; Lu H; Liu Q; Zhang X; Pan SY; Chen ZL; Yang L
    World J Surg Oncol; 2023 Apr; 21(1):129. PubMed ID: 37041581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apatinib for the treatment of gastric cancer.
    Geng R; Li J
    Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
    Scott LJ
    Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.